CINJ-Gynecology/Oncology

Medicine & Life Sciences

1. Ovarian Neoplasms 100%
2. Ovarian Epithelial Carcinoma 45%
3. Neoplasms 44%
4. TIC10 compound 18%
5. Single Nucleotide Polymorphism 14%
6. Nanotechnology 13%
7. Drug Therapy 13%
8. Therapeutics 13%
9. Case-Control Studies 12%
10. Survival 12%
11. Neoplasm Metastasis 12%
12. Breast Neoplasms 12%
13. Carboplatin 11%
14. Paclitaxel 11%
15. Endometrial Neoplasms 10%
16. Body Mass Index 10%
17. ATP Binding Cassette Transporter, Subfamily B, Member 1 9%
18. Genome-Wide Association Study 9%
19. Obesity 9%
20. Multiple Drug Resistance 9%
21. Gynecology 8%
22. Uterine Cervical Neoplasms 8%
23. Food 8%
24. Vemurafenib 7%
25. avelumab 7%
26. Population 7%
27. Pharmaceutical Preparations 7%
28. High-Throughput Nucleotide Sequencing 6%
29. Gynecologic Surgical Procedures 6%
30. Genes 6%
31. Selenium 6%
32. Confidence Intervals 6%
33. Drug Delivery Systems 6%
34. Data Warehousing 6%
35. Precision Medicine 6%
36. pembrolizumab 6%
37. Platinum 6%
38. Isotretinoin 5%
39. Tubal Sterilization 5%
40. Phytoestrogens 5%
41. Food and Beverages 5%
42. Interferon alpha-2 5%
43. Nanomedicine 5%
44. Odds Ratio 5%
45. Mutation 5%
46. Cell Movement 5%
47. Clinical Trials 5%
48. MicroRNAs 5%
49. Genetic Therapy 5%
50. Learning Curve 5%
51. Loss of Heterozygosity 5%
52. Healthy Diet 5%
53. Point-of-Care Systems 5%